Analysis showed that CDDO-Me had no effect on MDSCs levels in the peripheral blood, but it significantly improved the immune response in these patients.275 However, it is not clear whether the level of Nrf2 in MDSCs from peripheral lymphoid organs or tumor tissues is different.276 In addition to its anti-oxidative activity, Nrf2 may also contribute to a context-dependent regulation of MDSCs.277 In general, Nrf2 is a potential target in cancer treatment which deserves further investigation. This evidence concerns the gene NFE2L2 and cancer.